Trial Profile
Phase I and pharmacokinetic study of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Dec 2022
Price :
$35
*
At a glance
- Drugs Aldoxorubicin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors CytRx Corporation; LadRx Corporation
- 25 Nov 2009 New trial record.